- Home
- HLI vs BMRN Comparison
HLI vs BMRN Comparison
Compare HLI & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HLI
- BMRN
- Stock Information
- Founded
- HLI 1972
- BMRN 1996
- Country
- HLI United States
- BMRN United States
- Employees
- HLI N/A
- BMRN N/A
- Industry
- HLI Investment Managers
- BMRN Biotechnology: Pharmaceutical Preparations
- Sector
- HLI Finance
- BMRN Health Care
- Exchange
- HLI Nasdaq
- BMRN Nasdaq
- Market Cap
- HLI 12.8B
- BMRN 12.1B
- IPO Year
- HLI 2015
- BMRN 1999
- Fundamental
- Price
- HLI $185.51
- BMRN $57.50
- Analyst Decision
- HLI Buy
- BMRN Buy
- Analyst Count
- HLI 7
- BMRN 22
- Target Price
- HLI $193.67
- BMRN $93.43
- AVG Volume (30 Days)
- HLI 383.9K
- BMRN 2.2M
- Earning Date
- HLI 07-29-2025
- BMRN 08-04-2025
- Dividend Yield
- HLI 1.29%
- BMRN N/A
- EPS Growth
- HLI 41.61
- BMRN 152.82
- EPS
- HLI 5.82
- BMRN 2.71
- Revenue
- HLI $2,389,126,000.00
- BMRN $2,950,227,000.00
- Revenue This Year
- HLI $10.96
- BMRN $12.23
- Revenue Next Year
- HLI $11.58
- BMRN $9.99
- P/E Ratio
- HLI $31.87
- BMRN $21.25
- Revenue Growth
- HLI 24.80
- BMRN 19.36
- 52 Week Low
- HLI $133.48
- BMRN $52.93
- 52 Week High
- HLI $192.10
- BMRN $94.85
- Technical
- Relative Strength Index (RSI)
- HLI 68.30
- BMRN 55.64
- Support Level
- HLI $176.75
- BMRN $53.76
- Resistance Level
- HLI $185.40
- BMRN $56.25
- Average True Range (ATR)
- HLI 3.21
- BMRN 1.33
- MACD
- HLI 0.68
- BMRN 0.42
- Stochastic Oscillator
- HLI 95.76
- BMRN 86.90
About HLI Houlihan Lokey Inc.
Houlihan Lokey Inc is an investment bank with expertise in mergers and acquisitions, capital markets, financial restructuring, valuation, and strategic consulting. The firm serves corporations, institutions, and governments world-wide with offices in the United States, Europe, and the Asia-Pacific region. The company operates in three segments. In the Corporate Finance business segment, it provides M&A and capital markets advisory services. Through the Financial Restructuring business segment, the company advises on some of the complex restructurings around the world. The Financial and Valuation Advisory Services business segment provides valuation and financial opinion, and financial and strategic consulting practices in the United States.
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.